Comprehensive Cancer Center Core Support Grant

描述（由申请人提供）：UAB综合癌症中心是在其连续NCI核心赠款资助的第34个年头。 它是一个矩阵中心，并已被指定为在伯明翰的亚拉巴马大学的组织结构大学范围内的跨学科研究中心。 阿尔伯特·F. LoBuglio，医学博士，自1983年以来一直担任中心主任，并直接向大学教务长报告。 该中心有来自38个部门和大学的8个学院的249名成员。 年度直接研究支持为9880万美元，其中NCI支持3470万美元，其他同行评审支持4580万美元，非同行评审支持1820万美元。 该中心分为九个主要项目：肿瘤免疫学，结构生物学，病毒学，肿瘤生物学，实验治疗学，神经肿瘤学，妇女癌症，癌症化学预防和癌症控制与人口科学。 该中心的行政部门提供500多个账户（超过8000万美元）的财务管理、人员（464）、规划、协调和评估。 该中心提供15个核心赠款支持共享设施，涉及研究技术，生物统计学和生物信息学，组织采购，患者招募和保留。 癌症中心每年有3，444名肿瘤登记新患者，每年有779名患者参加临床试验，其中包括最近12个月的539名治疗试验。 重点是药物启动的试验和早期I期和II期试验。 该中心已成功地竞争了四个孢子赠款在乳腺癌，卵巢癌，脑肿瘤和胰腺癌。 癌症控制和人口科学计划的主要目标是少数民族的健康差距，重点是亚拉巴马和密西西比的农村，服务不足的人口。此外，在上一个资助期内，癌症预防和控制试验的累计费用超过24，828，主要与筛查和早期检测研究有关。 该中心已成功的发展资金组成部分与招聘重要的科学和领导个人和积极的试点项目计划。 内部委员会和外部咨询委员会为中心的高级领导提供建议。 该中心得到了大学和社区的大力支持，并在成功的资助和科学出版物方面取得了丰硕的成果。

DESCRIPTION (provided by applicant): The UAB Comprehensive Cancer Center is in its 34th year of continuous NCI Core Grant funding. It is a matrix center and has been designated as a University-wide Interdisciplinary Research Center in the University of Alabama at Birmingham organizational structure. Albert F. LoBuglio, M.D., has been Center director since 1983 and reports directly to the University Provost. The Center has 249 members derived from 38 departments and 8 schools of the University. Annual direct research support is $98.8 million with $34.7 million of NCI support, $45.8 million of other peer-reviewed support and $18.2 million of non-peer-reviewed support. The Center is organized into nine major programs: Tumor Immunology, Structural Biology, Virology, Tumor Biology, Experimental Therapeutics, Neuro-Oncology, Women's Cancer, Cancer Chemoprevention, and Cancer Control & Population Science. The Administration component of the Center provides fiscal management of more than 500 accounts (more than $80 million), personnel (464), planning, coordination, and evaluation. The Center provides 15 Core grant supported Shared Facilities involving research technology, biostatistics and bioinformatics, tissue procurement, and patient recruitment and retention. The Cancer Center has 3,444 tumor registry new patient accruals annually and places 779 patients on clinical trials annually including 539 accruals to therapeutic trials in the most recent 12 months. There is an emphasis on investigator-initiated trials and early phase I and II trials. The Center has successfully competed for four SPORE grants in Breast Cancer, Ovarian Cancer, Brain Tumors, and Pancreatic Cancer. The major thrust of the Cancer Control & Population Science Program is minority health disparity with an emphasis on rural, underserved populations in Alabama and Mississippi. In addition, there have been over 24,828 accruals to Cancer Prevention and Control trials over the last funding period primarily related to screening and early detection studies. The Center has had a successful development funding component with recruitment of vital scientific and leadership individuals and an active pilot project program. Internal committees and External Advisory Committee provide advice to the senior leadership of the Center. The Center has strong support by the University and the community with a productive record of successful grant support and scientific publications.